Aβ1-40 and Aβ1-42 plasmatic levels in stroke: Influence of pre-existing cognitive status and stroke characteristics

Current Alzheimer Research

Volumn 14, Issue 6, 2017, Pages 686-694

  Moulin, Solène ^a,c   Leys, Didier ^a,c   Schraen Maschke, Susanna ^b   Bombois, Stéphanie ^a,c   Mendyk, Anne Marie ^c   Muhr Tailleux, Anne ^d   Cordonnier, Charlotte ^a,c   Buée, Luc ^b   Pasquier, Florence ^a,c   Bordet, Régis ^a,c  

^a CHU Lille   (France)

^b JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^c UNIV LILLE   (France)

^d INSERM   (France)

Author keywords

Cerebral hemorrhage; Cerebral infarction; Cerebral ischemia; Cognitive decline; Cohort studies; Dementia; Plasma amyloid beta peptides; Stroke

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

AGE; BIOCHEMICAL ANALYSIS; BLOOD SAMPLING; CEREBROVASCULAR ACCIDENT; COGNITION ASSESSMENT; COGNITIVE DEFECT; DEMENTIA; DIABETES MELLITUS; HUMAN; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; PRIORITY JOURNAL; QUESTIONNAIRE; REVIEW; RISK FACTOR; SMOKING; STROKE PATIENT; SYSTEMATIC REVIEW; AGED; BLOOD; COHORT ANALYSIS; COMPLICATION; FEMALE; MALE; NONPARAMETRIC TEST; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMYLOID BETA-PEPTIDES; COGNITION DISORDERS; COHORT STUDIES; FEMALE; HUMANS; MALE; PEPTIDE FRAGMENTS; STATISTICS, NONPARAMETRIC; STROKE;

EID: 85020306789     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205012666151027141730     Document Type: Review

References (41)

1. Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol 8(11): 1006-1018 (2009).
2. Greenberg SM, Rebeck GW, Vonsattel JP, Gomez-Isla T, Hyman BT. Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy. Ann Neurol 38(2): 254-259 (1995).
3. Storey E, Cappai R. The amyloid precursor protein of Alzheimer's disease and the Abeta peptide. Neuropathol Appl Neurobiol 25(2): 81-97 (1999).
4. Mayeux R, Schupf N. Blood-based biomarkers for Alzheimer's disease: plasma Aβ40 and Aβ42, and genetic variants. NBA 32(1): S10-S19 (2011).
5. Iadecola C. The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathol 120(3): 287-296 (2010).
6. Thomas T, Thomas G, McLendon C, Sutton T, Mullan M. Betaamyloid-mediated vasoactivity and vascular endothelial damage. Nature 380(6570): 168-171 (1996).
7. Kliper E, Bashat DB, Bornstein NM, Shenhar-Tsarfaty S, Hallevi H, Auriel E. et al. Cognitive decline after stroke: relation to inflammatory biomarkers and hippocampal volume. Stroke 44(5): 1433-1435 (2013).
8. Mayeux R, Honig LS, Tang M-X, Manly J, Stern Y, Schupf N, et al. Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology 61(9): 1185-1190 (2003).
9. Blasko I, Jellinger K, Kemmler G, Krampla W, Jungwirth S, Wichart I, et al. Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: Prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine. Neurobiol Aging 29(1): 11-11 (2007).
10. Lambert J-C, Schraen-Maschke S, Richard F, Fievet N, Rouaud O, Berr C, et al. Association of plasma amyloid beta with risk of dementia: the prospective three-city study. Neurology 73(11): 847-853 (2009).
11. Fukumoto H, Tennis M, Locascio J, Hyman BT, Growdon JH, Irizarry MC. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol 60(7): 958-964 (2003).
12. Assini A, Cammarata S, Vitali A, Colucci M, Giliberto L, Borghi R, et al. Plasma levels of amyloid beta-protein 42 are increased in women with mild cognitive impairment. Neurology 63(5): 828-831 (2004).
13. Irizarry MC, Gurol ME, Raju S, Diaz-Arrastia R, Locascio JJ, Tennis M, et al. Association of homocysteine with plasma amyloid beta protein in aging and neurodegenerative disease. Neurology 65(9): 1402-1408 (2005).
14. Niwa K, Carlson GA, Iadecola C. Exogenous A beta1-40 reproduces cerebrovascular alterations resulting from amyloid precursor protein overexpression in mice. J Cereb Blood Flow Metab 20(12): 1659-1668 (2000).
15. Park L, Zhou P, Koizumi K, El Jamal S, Lou Previti M, Van Nostrand WE, et al. Brain and circulating levels of Aβ1-40 differentially contribute to vasomotor dysfunction in the mouse brain. Stroke 198-204 (2012).
16. Gurol ME, Irizarry MC, Smith EE, Raju S, Diaz-Arrastia R, Bottiglieri T, et al. Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology 66(1): 23-29 (2006).
17. Gomis M, Sobrino T, Ois A, Millán M, Rodríguez-Campello A, de la Ossa N, et al. Plasma beta-amyloid 1-40 is associated with the diffuse small vessel disease subtype. CORD Conf Proc 40(10): 3197-3201 (2009).
18. Lee PH, Bang OY, Hwang EM, Lee JS, Joo US, Mook-Jung I, et al. Circulating beta amyloid protein is elevated in patients with acute ischemic stroke. J Neural Transm 112(10): 1371-1379, (2005).
19. Bibl M, Welge V, Schmidt H, Esselmann H, Mollenhauer B, Lewczuk P, et al. Plasma amyloid-betapeptides in acute cerebral ischemia: a pilot study. J Clin Lab Anal 26(4): 238-245 (2012).
20. Del Zoppo GJ. Bleeding in the brain: Amyloid-beta may keep clots away. Nat Med 15(10): 1132-1133 (2009).
21. Casolla B, Dequatre-Ponchelle N, Rossi C, Hénon H, Leys D, Cordonnier C. Heavy alcohol intake and intracerebral hemorrhage: characteristics and effect on outcome. Neurology 79(11): 1109-1115 (2012).
22. Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24(1): 35-41 (1993).
23. Jorm AF, Jacomb PA. The informant questionnaire on cognitive decline in the elderly (IQCODE): socio-demographic correlates, reliability, validity and some norms. Psychol Med 19(4): 1015-1022 (1989).
24. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol 149(2): 351-356 (1987).
25. Hansson O, Zetterberg H, Vanmechelen E, Vanderstichele H, Andreasson U, Londos E, et al. Evaluation of plasma Aβ40 and Aβ42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging 31(3): 357-367 (2010).
26. Kiss JZ, Troncoso E, Djebbara Z, Vutskits L, Muller D. The role of neural cell adhesion molecules in plasticity and repair. Brain Res Rev 36(2): 175-184 (2001).
27. Huang X, Choi J-K, Park SR, Ha Y, Park H, Yoon SH, et al. GMCSF inhibits apoptosis of neural cells via regulating the expression of apoptosis-related proteins. Neurosci Res 58(1): 8-8 (2007).
28. Henon H, Pasquier F, Durieu I, Godefroy O, Lucas C, Lebert F, et al. reexisting dementia in stroke patients. Baseline frequency, associated factors, and outcome. Stroke 28(12): 2429-2436 (1997).
29. Cordonnier C, Leys D, Dumont F, Deramecourt V, Bordet R, Pasquier F, et al. What are the causes of pre-existing dementia in patients with intracerebral haemorrhages? Brain 133(11): 3281-3289 (2010).
30. Blennow K, Meyer G, Hansson O, Minthon L, Wallin A, Zetterberg H, et al. Evolution of Abeta42 and Abeta40 levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer's disease: a multicenter assessment. J Nutr Health Aging 13(3): 205-208 (2009).
31. Yaffe K, Weston A, Graff-Radford NR, Satterfield S, Simonsick EM, Younkin SG, et al. Association of plasma-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA 305(3): 261-266 (2011).
32. Leys D, Hénon H, Mackowiak-Cordoliani MA, Pasquier F. Poststroke dementia. Lancet Neurol 4(11): 752-759 (2005).
33. van Dijk EJ, Prins ND, Vermeer SE, Hofman A, Van Duijn CM, Koudstaal PJ, et al. Plasma amyloid? apolipoprotein E, lacunar infarcts, and white matter lesions. Ann Neurol 55(4): 570-575 (2004).
34. Head E, Doran E, Nistor M, Hill M, Schmitt FA, Haier RJ, et al. Plasma amyloid-β as a function of age, level of intellectual disability, and presence of dementia in Down syndrome. J Alzheimers Dis 23(3): 399-409 (2011).
35. Shah NS, Vidal JS, Masaki K, Petrovitch H, Ross GW, Tilley C, et al. Midlife blood pressure, plasma-amyloid, and the risk for Alzheimer disease: the honolulu asia aging study. Hypertension 59(4): 780-786 (2012).
36. Sato N, Morishita R. Plasma Aβ: a possible missing link between Alzheimer disease and diabetes. Diabetes 62(4): 1005-1006 (2013).
37. Schupf N, Zigman WB, Tang M-X, Pang D, Mayeux R, Mehta P, et al. Change in plasma Aß peptides and onset of dementia in adults with Down syndrome. Neurology 75(18): 1639-1644 (2010).
38. Ridwan S, Bauer H, Frauenknecht K, Pein H, Sommer CJ. Distribution of granulocyte–monocyte colony-stimulating factor and its receptor α-subunit in the adult human brain with specific reference to Alzheimer’s disease. J Neural Transm 119(11): 1389-1406 (2012).
39. Strekalova H, Buhmann C, Kleene R, Eggers C, Saffell J, Hemperly J, et al. Elevated levels of neural recognition molecule L1 in the cerebrospinal fluid of patients with Alzheimer disease and other dementia syndromes. Neurobiol Aging 27(1): 9-9 (2005).
40. Rentzos M, Michalopoulou M, Nikolaou C, Cambouri C, Rombos A, Dimitrakopoulos A, et al. The role of soluble intercellular adhesion molecules in neurodegenerative disorders. J Neurol Sci 228(2): 129-135 (2005).
41. Xu F, Lou Previti M, Van Nostrand WE. Increased severity of hemorrhage in transgenic mice expressing cerebral protease nexin-2/amyloid beta-protein precursor. Stroke 38(9): 2598-2601 (2007).